Status:
COMPLETED
Effects of INDUS810 on Body Composition, Muscular Performance, and Training Adaptations
Lead Sponsor:
The Center for Applied Health Sciences, LLC
Collaborating Sponsors:
Indus Biotech
Conditions:
Weakness, Muscle
Eligibility:
MALE
18-45 years
Phase:
NA
Brief Summary
The purpose of this 12-week, interventional study is to determine the effects of oral supplementation with Indus810 (dietary supplement with active ingredient Fenugreek) on body composition, muscular ...
Detailed Description
This 12-week study is a randomized, parallel-group, placebo-controlled, clinical trial of N=66 recreationally, but normal to moderately overweight/obese male subjects to be recruited at a single inves...
Eligibility Criteria
Inclusion
- Provide voluntary signed and dated informed consent.
- Be in good health as determined by medical history and routine blood chemistries.
- Age between the ages of 18 and 45.
- Body Mass Index (BMI):
- 22-25; Waist:Hip Ratio 0.9-1
- 25-35; Waist:Hip Ratio 0.85-1
- Normotensive (supine, resting systolic blood pressure \<140 mm Hg and diastolic blood pressure \< 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5 minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.
- Normal supine, resting heart rate (\<90 per minute).
- Willing to duplicate their previous 24-hour diet, and fast for 8-10 hours prior each of the treatments.
- Has been participating in regular exercise training, at least 3 days per week, for the past 1-2 months.
Exclusion
- History of diabetes.
- Use of any pre-workout or creatine containing products in the last 4 weeks.
- History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
- Prior gastrointestinal bypass surgery (Lapband, etc.).
- Other known gastrointestinal or metabolic diseases that might impact absorption or amino acid metabolism, e.g. short bowel syndrome, diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU).
- Chronic inflammatory condition or disease (e.g. rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.). -Known sensitivity to any ingredient in the test formulations as listed in the Certificates- of-Analysis.
- Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
- Concomitant use of corticosteroids or testosterone replacement therapy (ingestion, injection, or transdermal).
- Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoint or place the subject at increased risk of harm if they were to participate.
Key Trial Info
Start Date :
July 11 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2019
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT03850106
Start Date
July 11 2018
End Date
April 30 2019
Last Update
February 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Center for Applied Health Sciences
Stow, Ohio, United States, 44224